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Catalytic processes play critical roles in the modern-day industrial
syntheses of many commonplace materials such as plastics, fuel
production, electronics, and pharmaceuticals. Transition metal
catalysts may become homogenously embedded within solid
nanomaterials during their synthetic scheme, which may result in many
deleterious effects on both the construction and durability of the
material and its intended functionality. Traditional purification methods
of these materials rely upon harsh reaction conditions that may either
affect or allow for specific functionalities.
Arylazothioformamide (ATF) ligands have proven to be a mild
alternative for their ability to chelate these solid transition metal
catalysts. This work will describe the synthetic steps towards
developing a versatile library of ATF ligands, the characterization of
those synthesized, and initial chelation studies directed towards the
purification of pharmaceutical drugs which employ catalytic processes
in their production.
Originally, Jensen1 synthesized the (ATF) ligands and metal
complexation studies were reported by Krebs, and Bechegaard2
citing complexes of Palladium (Pd), Platinum (Pt), Copper (Cu), and
Nickel (Ni) metals. Intense absorption changes were noted and X-ray
crystallography revealed a 2:1 ligand-to-metal (bis) complexation
ratio. Few variations of the original ligands (again by Krebs) were
developed with slight further advancement or applications.3
This project has been directed towards developing new variations of
the original (ATF) ligand synthesized by Jensen, as well as studying
chelation of the original ligand with transition metal catalysts utilized
during pharmaceutical synthesis.
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Generic construction of the (ATF) ligand
Beginning with phenyl hydrazine, CS2 is added to create the thiocarbamic
acid , addition of KOH followed by methyl iodide converts the compound to the
thioester. Upon solvent removal, the secondary amine is added and refluxed to
prepare the azothiocarbazide, which is then finally exposed to air and
undergoes oxidization to the various arylazothioformamide (ATF) ligands.
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A⇒ Jensen’s Original Ligand (This Study)
B-F ⇒ future coordination complex studies
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Additional metal complexation studies will be carried out with various
transition metals with the modified ligands already synthesized.
Synthetic modifications to the original ligand will be carried out in the
future, with an interest in developing a new class of semi-
perfluorinated and hydrophilic ATF ligands. This will potentially enable
enhanced metal extraction from a multitude of immiscible phases
(aqueous, organic, and a distinct fluorous phase). Further chelation
studies will be carried out on atom-transfer radical polymerization
(ATRP) initiated polymers, carbon nanotubes, and metal impurities in
solution. Eventually, studies will be directed towards providing an
improved method of recycling catalytic materials and various metals.
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The Absorbance Spectra Graphs are interesting for a number of reasons:
Cu(I)Br and Copper Wire and Copper Salts:
• Three distinct isosbestic points can be see on the graph.
• After ten equivalents of Copper(I)Bromide are added to the pure ligand, a dramatic shift in
the absorbance signature can be seen.
• This data suggests, but does not entirely confirm that the (ATF) ligand is chelating the
Copper metal, forming a coordination complex, as see in the crystal structure above.
• This also suggests that these ATF ligands are capable of chelating these metals (Copper or
Palladium) in various oxidative states.
Naproxen and Ibuprofen:
• Both Naproxen and Ibuprofen exhibit substantial changes in their absorbance signatures
when treated with the ATF ligand. Naproxen shows the most dramatic shift, which may
suggest more trace metal impurities are within the drug
• Future studies of this project will involve treating these pharmaceutical drugs with the ATF
ligand and analyzing the treated drug with Inductively-Coupled Plasma-Mass Spectrometry
to check for residual trace metal impurities
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